BioMedNewsBreaks

MondayOct 26, 2026 10:20 am

BioMedNewsBreaks — Adaptogenics Health Corp. (CSE: ADPT) Draws Sector Attention as RFK Jr. Pushes for Safer, Regulated Peptide Access, iHeartRadio Reports 

This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.  Adaptogenics (CSE: ADPT) is in focus as Health and Human Services Secretary Robert F. Kennedy Jr. advocates expanding access to peptide drugs through a regulated marketplace. According to iHeartRadio, citing Reuters, Kennedy said during an Oct. 20 appearance on Fox News that the Trump administration is working to ensure Americans can obtain peptides manufactured in inspected facilities. Acknowledging that the peptides under consideration have not been approved by the Food and Drug Administration ("FDA") as safe or effective, Kennedy argued that consumers would continue…

Continue Reading

MondayOct 26, 2026 10:13 am

BioMedNewsBreaks — Adaptogenics Health Corp. (CSE: ADPT) in Focus as Trump Administration Advances Peptide Access Policy, AP Reports 

This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.  Adaptogenics (CSE: ADPT) is positioned in a peptide market drawing increased attention as the Trump administration advances plans to ease restrictions on certain peptide compounds. According to The Associated Press via NBC News, the Department of Health and Human Services has submitted an interim access policy to the White House for review that could allow specialty pharmacies to temporarily produce certain peptides, including BPC-157, which is promoted for muscle growth and injury recovery. The proposal follows a July recommendation by external Food and Drug…

Continue Reading

MondayOct 26, 2026 9:10 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Peer-Reviewed Study Identifying Four-Gene Signature in Liver Cancer Using AI Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced the publication of a peer-reviewed study in Biomedicines demonstrating how its AI-powered PDAOAI platform helped identify a four-gene prognostic signature in hepatocellular carcinoma ("HCC"), a form of liver cancer. Published Oct. 23, 2026, the study used Partitioned Literature Aggregation ("PLA"), Oncotelic's patented algorithm running on PDAOAI, alongside gene-expression and survival analyses to identify four genes: FKBP1A, EIF4E, RRAGC and PPARGC1A. The signature's association with patient survival was independently validated in a Japanese HCC cohort of 203 patients. The findings support patient stratification for clinical trials of Sapu003, an intravenous formulation of everolimus. Oncotelic Chief Business…

Continue Reading

WednesdayOct 21, 2026 3:00 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Aims for Greater Precision in Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) is developing antibody-based cancer therapies designed to improve treatment selectivity and potentially reduce toxicity to healthy tissues. At the center of its strategy is the proprietary BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) platform, which uses two complementary molecules designed to activate cancer-killing activity only when both recognize targets on the same tumor cell. The company is applying this approach to antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), with a particular focus on solid tumors. VERAXA reported promising preclinical findings for its lead BiTAC-TCE program, including selective targeting of cells expressing both intended targets and improved safety alongside comparable…

Continue Reading

TuesdayOct 20, 2026 3:17 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Scales GelrinC Manufacturing Amidst Development Progress

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel technology, designed to promote the regeneration of durable, natural-like cartilage in patients with painful knee cartilage injuries. The cell-free, off-the-shelf implant temporarily fills cartilage defects before gradually resorbing as surrounding tissue regenerates. Long-term MRI findings and peer-reviewed Phase II clinical data have provided evidence of cartilage maturation and durable structural repair, while the company has reported greater pain improvement than traditional microfracture. Regentis has treated 43 of 80 planned patients in its U.S. pivotal Phase III trial, with enrollment expected to conclude around the end of 2026, and is preparing for…

Continue Reading

TuesdayOct 20, 2026 9:00 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present AI-Enabled Drug Discovery Keynote at 22nd Drug Discovery Strategic Summit

Oncotelic Therapeutics (OTCQB: OTLC) announced that Chief Business Officer Saran Saund will deliver the opening keynote on the second day of the 22nd Drug Discovery Strategic Summit on Oct. 22, 2026, at 9 a.m. Pacific Time in Millbrae, California. The presentation will explore partition and aggregation as an organizing principle for AI-enabled drug discovery, emphasizing how complex research questions can be divided into focused investigations and findings combined to develop testable hypotheses. Saund will discuss the company's proprietary PDAOAI platform, which indexes approximately 29 million PubMed abstracts, along with its international intellectual property strategy, planned expansion into genetic discovery and…

Continue Reading

MondayOct 19, 2026 3:21 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in Men’s Fitness Article Examining Unbuzzd Clinical Trial Results

Quantum BioPharma (NASDAQ: QNTM) was featured in a Men's Fitness article by Lakshan Weeraratne examining clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The article highlights findings from a company-sponsored, placebo-controlled study involving 26 healthy adults, with 24 completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with…

Continue Reading

MondayOct 19, 2026 11:07 am

BioMedNewsBreaks — ECGI Holdings Inc. (OTC: ECGI) Highlights Avanta Acquisition and Growing Opportunities in $5.3 Trillion U.S. Healthcare Market 

ECGI Holdings (OTC: ECGI) is featured in an AINewsWire editorial examining the shift toward preventive, coordinated healthcare and the growing role of artificial intelligence in improving patient outcomes and managing costs. The editorial highlights ECGI's acquisition of Avanta Group, a developing integrated healthcare platform encompassing Medicare Advantage insurance, management services, AI-enabled technology, consumer health and healthcare infrastructure. The acquisition positions ECGI to pursue opportunities in a U.S. healthcare market that reached $5.3 trillion in 2024, with Medicare Advantage payments projected to total $574 billion in 2026. The editorial also discusses the potential for integrated technology and care coordination to improve…

Continue Reading

FridayOct 16, 2026 3:40 pm

BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Highlights Insider Buying Alongside Its Integrated Healthcare Technology Strategy

Recent SEC Form 4 filings disclosed open-market purchases of Nano-X Imaging Ltd.’s (NASDAQ: NNOX) (“Nanox”) ordinary shares by CEO Erez Meltzer and Board Director Dan Suesskind, adding to purchases reported in recent months by Meltzer, Suesskind and Board Director Nogah Keinan. The transactions reflect share purchases made directly in the open market by the company’s senior leadership and board members, with additional details available in the respective SEC filings. This comes as Nanox continues to advance its integrated medical imaging and healthcare services platform, which combines proprietary digital X-ray technology, AI-powered imaging analytics, cloud-based software, remote radiology services and healthcare…

Continue Reading

FridayOct 16, 2026 2:18 pm

BioMedNewsBreaks — Nanox Imaging Ltd. (NASDAQ: NNOX) Subsidiary Signs Distribution Agreement to Commercialize HealthOST in Italy

Nanox (NASDAQ: NNOX) announced that its subsidiary, Nanox AI Ltd., has entered into a distribution agreement with Technologic s.r.l., an Italian company affiliated with Tecnologie Avanzate, to commercialize its AI-powered bone health solution, HealthOST, in Italy. The agreement is intended to expand Nanox AI commercial presence in the Italian market, leveraging Technologic experience and local market knowledge. HealthOST analyzes eligible routine CT scans to provide qualitative and quantitative assessments of the spine, helping clinicians identify patients who may benefit from further evaluation for musculoskeletal conditions such as osteoporosis. To view the full press release, visit https://ibn.fm/y9Zro About Nanox Nanox (NASDAQ:…

Continue Reading